Evidence map›Paper›PMID 42327583›Full record

ArticleJournal of Cancer2026

Po-Ting Lin, Wei Teng, Wei-Ting Chen, Yu-De Chu, Chung-Wei Su, Yi-Chung Hsieh, Chen-Chun Lin, Yung-Chang Lin, Chun-Yen Lin, Chau-Ting Yeh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Po-Ting LinDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Wei TengDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Wei-Ting ChenDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Yu-De ChuLiver Research Center, Linkou Chang Gung Memorial Hospital, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Chung-Wei SuDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Yi-Chung HsiehDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Chen-Chun LinCollege of Medicine, Chang Gung University, No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan.
Yung-Chang LinCollege of Medicine, Chang Gung University, No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan.
Chun-Yen LinDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Chau-Ting YehDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Shi-Ming LinDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Genomic alterations have been reported to correlate with patients' response to immune checkpoint inhibitor (ICI) therapy in hepatocellular carcinoma (HCC). The present study aimed to examine whether single nucleotide polymorphism (SNP) is associated with ICI treatment-related side effects and progression-free survival (PFS) in HCC patients. Methods: This retrospective study included 96 patients with HBV-related HCC receiving ICI (atezolizumab plus bevazizumab) therapy between 2020 and 2023. Five SNPs derived from a previous genome-wide association study linking to chemotherapy responses in HCC patients were included. Their predictive values for PFS and side effects were examined. Results: After ICI therapy, patients with Conclusions: Genetic variant of an SNP,

Indexed as

hepatocellular carcinoma (HCC)progression-free survival (PFS)rs6752303side effectssingle nucleotide polymorphism (SNP)

Identifiers

PMID42327583
PMCPMC13280630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.